
Real-world data used to combat COVID-19
29 July 2022
- Monitoring data on hospitals’ utilisation and capacity rates: location and number of licensed beds, staffed beds, ICU beds, and total bed utilisation rates
- Plan for critical care based on epidemiological data on COVID-19 and clinical outcomes: modeling tools development to identify surges in clinical demand, as well as best- and worst-case scenarios of COVID-19-induced strain on hospital capacity
- High-risk patient identification: respiratory issues, social isolation, exposure risk survey (recent travel, attendance at large public events, symptoms of the virus), patient data collection to better understand risk factors (genetic, clinical, and environmental data), COVID-19 impact on certain communities assessment
- Modeling framework for different types, intensities, and durations of interventions to be implemented and evaluation of the effect on the spread of the virus over time
Click here to learn more.
About SVMPharma
SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.
About DISTILL
DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
Ref: RWEJUL2022KRC